4 unchanged sentences
On October 10, 2018, we sold 18,000,000 shares of our common stock at a public offering price of $18.00 per share for an aggregate gross offering price of $324.0 million.
−Removed: An additional 2,700,000 shares were sold pursuant to the underwriters’ option to purchase additional shares with a public offering price of $18.00 per share for additional gross proceeds of $48.6 million.
+Added: An additional 2,700,000 shares were sold pursuant to the underwriters’ option to purchase
+Added: additional shares with a public offering price of $18.00 per share for additional gross proceeds of $48.6 million.
On October 15, 2018, we completed our IPO.
6 unchanged sentences
Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank money market accounts.
−Removed: Through September 30, 2020, we have used $153.7 million of the net proceeds from our IPO.
−Removed: We are investing these funds in some combination of short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S.
−Removed: We expect to use the net proceeds from our IPO to fund our clinical development plans and the build-out of our manufacturing facility in Newark, California.
−Removed: We cannot predict with certainty all of the particular uses for the net proceeds from our IPO, or the amounts that we will actually spend on the uses set forth above.
−Removed: The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to access additional financing, the relative success and cost of our research, preclinical and clinical development programs and whether we are able to enter into future licensing arrangements.
−Removed: As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from our IPO.
+Added: Through March 31, 2021, we have used $276.8 million of the net proceeds from our IPO.
+Added: The net proceeds from our IPO are being used, together with our cash and cash equivalents, short-term and long-term investments, to fund continued advancement of our product pipeline, with the balance to be used to fund working capital and other general corporate purposes, which may include licensing, acquiring or investing in complementary businesses, technologies, products or assets.
Defaults Upon Senior Securities.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.